Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

PP405 is the most promising future treatment for hair loss, aiming to reactivate dormant hair follicles. Clascoterone 5% is the most promising near-term drug, while current strategies include using finasteride or dutasteride to stabilize hair loss and minoxidil to stimulate growth.

Hair loss is linked to scalp fibrosis and tension, which result from chronic mechanical stress and androgenic signaling. Treatments include blocking androgens with finasteride, promoting hair growth with topical minoxidil, and improving scalp mobility through exercises.

PP405 and ABS-201 are promising treatments for male pattern baldness. PP405 shows rapid hair growth in human trials, while ABS-201 shows significant regrowth in animal studies but is still in early human trials.

Increased Malassezia and Cutibacterium in the scalp microbiome are linked to higher sebum production and inflammation in androgenetic alopecia (AGA). Treatments include ciclopirox shampoo, benzoyl peroxide shampoo, clobetasol propionate, calcipotriol, minoxidil, finasteride, and dutasteride.

SCUBE3 and GT20029 are potential treatments for hair loss, with SCUBE3 stimulating hair growth and GT20029 protecting against DHT. A combined approach using SCUBE3, finasteride or dutasteride, and later GT20029 could provide a comprehensive treatment for androgenetic alopecia.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Rotenone, a natural plant extract, may promote hair growth by increasing LDH activity and blocking MPC in the scalp, but it carries risks due to its toxicity. The suggested formulation includes Barbasco extract, DMSO, propylene glycol or PEG-400, ethanol, and a carrier oil.

RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.

The user has been mixing finasteride with stemoxydine for hair loss and is considering switching to a less expensive product with a different ingredient list. They are questioning if the new product's higher water content compared to alcohol will affect the finasteride's solubility.

A 26-year-old male started minoxidil treatment for male-pattern baldness and saw significant regrowth in three months. He is considering finasteride but is hesitant due to potential side effects.

The conversation is about planning a hair transplant in Turkey, with advice on choosing clinics and doctors, focusing on factors like doctor involvement, clinic reputation, and realistic graft limits per session. Users recommend not exceeding 4000 grafts per session to avoid donor area damage and suggest considering two separate procedures for better graft survival.

The user experienced significant hair growth after adding ostrich oil and weekly microneedling to their existing treatment of topical dutasteride and minoxidil. They believe the combination of ostrich oil and microneedling contributed to the results, although some users suggest the increased microneedling frequency might be the main factor.

The conversation humorously critiques common hair loss discussions, mentioning treatments like Minoxidil, finasteride, and RU58841. It highlights confusion over progress pictures, pet safety concerns, and unrealistic expectations for new treatments.

Hair loss treatments range from common options like biotin, minoxidil, and finasteride to more obscure methods like RU58841 and experimental drugs. Hair transplants are widely known, while treatments like stool transplants and spironolactone are less common.

Minoxidil, finasteride, and dutasteride are commonly used for hair loss treatment, with some users seeing them as long-term solutions while awaiting future advancements like hair follicle cloning or gene engineering. Some users also consider additional treatments like anti-inflammatories, PRP, and hair transplants, but remain skeptical about a definitive cure.

Minoxidil and finasteride are the only FDA-approved treatments for androgenetic alopecia, while newer treatments like clascoterone, PP405, NV-623/624, AMP-303, and RU58841 are still experimental with varying levels of evidence. Clascoterone shows the most promise due to strong human data, while AMP-303 has notable early human trial results; RU58841 lacks human data and remains experimental.

The user is unhappy with their hair regrowth after one year on oral finasteride and minoxidil, considering a hair transplant. Many suggest shaving the head or trying more aggressive treatments like RU58841, dutasteride, microneedling, and hair transplants.

The conversation humorously discusses unconventional and satirical hair loss treatments involving urine and feces. Participants joke about these methods as alternatives to traditional treatments like Minoxidil and finasteride.

The conversation discusses hair loss treatments, focusing on insulin resistance, microneedling with topical melatonin, and stress reduction. Users express skepticism about the advice, preferring proven treatments like minoxidil and finasteride, while some mention alternative methods like dermal incisions and verteporfin for reducing fibrosis.

DHT is not the only cause of male pattern hair loss; genetic sensitivity, inflammation, and fibrosis also contribute. GHK-Cu, a copper peptide, is being explored as an alternative treatment to finasteride and minoxidil, showing potential in improving follicle health.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.

Topical pirfenidone is highlighted as an effective anti-inflammatory and anti-fibrotic treatment for hair loss, particularly in addressing perifollicular fibrosis, which may enhance the effectiveness of standard treatments like finasteride and minoxidil. The user also uses calcipotriol, MCT oil, ciclopirox shampoo, and benzoyl peroxide shampoo as part of their regimen.

The user is experiencing hair thinning despite using finasteride and minoxidil with added tretinoin, and is considering switching to dutasteride. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

The user is seeking advice on hair loss treatment after three months on finasteride, having stopped minoxidil due to a rash, and is now using nanoxidil. Suggestions include switching to oral minoxidil, adding dutasteride, and incorporating microneedling for better results.

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

PP405 is considered as a potential hair regrowth treatment, but users are skeptical due to past product failures. They compare it to Minoxidil and Finasteride, questioning its effectiveness and the intentions of pharmaceutical companies.

A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.

A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.